|
Title
|
|
|
|
Bacteriophage therapy : advances in formulation strategies and human clinical trials
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Recently, a number of phage therapy phase I and II safety trials have been concluded, showing no notable safety concerns associated with the use of phage. Though hurdles for efficient treatment remain, these trials hold promise for future phase III clinical trials. Interestingly, most phage formulations used in these clinical trials are straightforward phage suspensions and not much research has focused on the processing of phage cocktails in specific pharmaceutical dosage forms. Additional research on formulation strategies and stability of phage-based drugs will be of key importance, especially with phage therapy advancing towards phase III clinical trials. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Annual Review of Virology. - Palo Alto, 2014, currens
| |
|
Publication
|
|
|
|
Palo Alto
:
Annual reviews
,
2015
| |
|
ISSN
|
|
|
|
2327-056X
| |
|
DOI
|
|
|
|
10.1146/ANNUREV-VIROLOGY-100114-054915
| |
|
Volume/pages
|
|
|
|
2
(2015)
, p. 599-618
| |
|
ISI
|
|
|
|
000364397900027
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|